1[1]Dayan E,Rosa FW:F et al. Ambiguous genitalia associated with sex hormones use early in pregnancy. Food and Administration,Division of Drug Experience. ADR highlights 1981,1～14.
2[2]Heinonen OP,Slone D,Shapiro S:Birth defects and drugs in pregnancy. Littleton, MA : Publishing Sciences Group, 1977.
3[3]Heinonen OP,Slone D,Monson RR,et al. Cardiovasvular birth defects and antenatal exposure to female sex hormones. N Engl J Med1977,296:67～70.
4[4]Wiseman RA,Dodds-Smith IC:Cardiovascular birth defects and antenatal exposure to female sex hormones :a revaluation of some base data. Teratology1984,30:359～370.
5[5]Wilson JG,Brent RL:Are female sex hormones teratogenic? Am J Obstet Gynecol 1981,141: 567～ 590.
6[6]Dahlberg K: Some effects of depo-medroxyprogesterone acetate(DMPA) :observation in the nursing infant and in the long-term user. Int J Gynecol Obstet 1982,20:43～48.
7[7]Katz Z,Lancet M,Scomik J,Chemke J,et al. Teratogenicity of progestogins given during the first trimester of pregnancy.ObstetGynecol1985,65:775780.
8[8]ReseguieLJ,Hick JF,Bruen JA,et al. Congenital malformations among offspring exposed in utero to progestins,Olmsted County,Minnesota,Fertil Steril 1985,43:514～ 519.
7Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: evaluation and management [ J ]. BMJ, 2004, 7 (17):152-155.
8丰有吉,沈铿.妇产科学[M].第1版.北京:人民卫生出版社,2006:116-118.
9Willams JK. Noncontraceptive benefits of oral contraceptive use an evidence -based approach. Int J Fertil Womens Med, 2000.45 (3) :241-247.
10Burnhill MS. The use of a large - scale surveillance system in planned parenthood federation of America clinic's to monitor cardiovascular events in users of combination oral contraceptives. Int J Fertil Womens Med. 1999,44(1) ; 19 -30.
